CaCC Inhibitors
1 drugsAbout CaCC
CaCC's biological function and mechanism are not detailed in the provided context.
There is currently no genetic evidence available to support CaCC as a therapeutic target for any specific disease.
CaCC is targeted by one approved small molecule drug, MYTESI, marketed by NAPO PHARMS INC for other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Diarrhea with only 1 trials.
Top Drugs
NAPO PHARMS INC is the only company with an approved drug targeting CaCC.
Low competition may indicate high entry barriers or limited market potential.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CaCC, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide differentiation.
Clinical Trials 17 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 5 | 2 | 0 | 3 | 100% |
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
| Phase 4 | 5 | 3 | 2 | 0 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2012 - 2012)
The first and only drug approval for CaCC was MYTESI in 2012.
The lack of recent approvals suggests a saturated market or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 14 clinical trials targeting CaCC.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities